ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

メタラミノール

Metaraminol

HCID 5906
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
54-49-9
標準SMILES
C[C@H](N)[C@H](O)c1cccc(O)c1
InChIKey
WXFIGDLSSYIKKV-RCOVLWMOSA-N
分子式
C9H13NO2
平均分子量
167.2 g/mol
単同位体質量
167.09462866

概要

Metaraminol is a member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension. It has a role as a sympathomimetic agent, an alpha-adrenergic agonist and a vasoconstrictor agent.

名称と識別子

優先名称
Metaraminol
IUPAC
3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol
現地名
メタラミノール
英語名
Metaraminol
分子式
C9H13NO2
分子量
167.21

名称と別名

metaraminolL-MetaraminolMetaradrineHydroxynorephedrinem-Hydroxypropadrine1-MetaraminolPressorolm-Hydroxy norephedrine(-)-Erythro-metaraminolIcoral B54-49-9m-Hydroxyphenylpropanolamine
名称をさらに表示
(R)-α-[(S)-1-アミノエチル]-3-ヒドロキシベンゼンメタノールアラミンメタラドリン(-)-erythro-メタラミノールメタラミノールプレッソネックス3-[(1R,2S)-1-ヒドロキシ-2-アミノプロピル]フェノール(R)-α-[(S)-1-アミノエチル]-m-ヒドロキシベンジルアルコール(-)-3-[(1R,2S)-2-アミノ-1-ヒドロキシプロピル]フェノールイコラルB1-メタラミノールプレッソロール[αR,(-)]-3-ヒドロキシ-α-[(S)-1-アミノエチル]ベンゼンメタノール(-)-メタラミノール3-[(1R,2S)-2-アミノ-1-ヒドロキシプロピル]フェノール3-((1R,2S)-2-amino-1-hydroxypropyl)phenol(1-Aminoethyl)-3-hydroxybenzenemethanolC07146icoralbpressonexCCRIS 8465
Metaraminolum3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol3-Hydroxyphenylisopropanolamine1-(m-Hydroxyphenyl)-2-amino-1-propanol2-Amino-1-(m-hydroxyphenyl)-1-propanolalpha-(m-Hydroxyphenyl)-beta-aminopropanolalpha-(1-Aminoethyl)-m-hydroxybenzyl alcoholm-Hydroxy-alpha-(1-aminoethyl)-benzyl alcohol

物性

構造計算による物性補完中

XLogP
-0.4
極性表面積
66.5 Ų
水素結合供与体数
3
水素結合受容体数
3
回転可能結合数
2
重原子数
12
形式電荷
0
複雑度
140

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 3 件

log Kow= -0.27

0.6

-0.27

Solubility · 3 件

SOLUBILITY IN ALCOHOL: 1 G/100 ML /BITARTRATE/

INSOL IN CHLOROFORM, ETHER, ACETONE /BITARTRATE/

1.28e+01 g/L

Human DrugsPharmaceuticals
DecompositionWhen heated to decomposition it emits toxic fumes of nitroxides.
Melting Point107.5 °C
Physical DescriptionSolid
Dissociation Constants8.79
Other Experimental Properties · 5 件

Crystals; MP: 176-177 °C; pH of 1% aq soln: about 3.5; freely sol in water /l-form Bitartrate/

PRACTICALLY ODORLESS /BITARTRATE/

Hygroscopic; Specific optical rotation: -19.75 deg @ 20 °C/D; freely sol in water /l-form hydrochloride/

Crystals; MP: 190 °C; specific optical rotation: -21.66 deg @ 20 °C/D; sol in water /l-form oxalate dihydrate/

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

Other Safety InformationIMAP assessments - Benzenemethanol, .alpha.-(1-aminoethyl)-3-hydroxy-, [R-(R*,S*)]-: Environment tier I assessment
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全と保護具

Storage ConditionsMetaraminol bitartrate injection should be stored at room temperature and protected from light. Freezing and temperatures above 40 °C should be avoided. /Metaraminol bitartrate/
Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

MAO INHIBITORS...HAVE THE POTENTIAL FOR DRUG INTERACTION WITH METARAMINOL THROUGH INHIBITION OF OXIDATIVE DEAMINATION OF SYMPATHOMIMETIC AMINES. THE RESULT MAY BE AN INCREASED TISSUE STORE OF NOREPINEPHRINE, WHICH WILL PRODUCE A HEIGHTENED HYPERTENSIVE RESPONSE SECONDARY TO THE INDIRECT ACTIONS OF METARAMINOL. /BITARTRATE/

GUANETHIDINE, RESERPINE, & METHYLDOPA AFFECT POSTGANGLIONIC NERVE ACTIVITY, EITHER BY DECREASING NOREPINEPHRINE STORES OR BY EFFECTING ITS RELEASE. THEREFORE, THESE DRUGS WILL INTERFERE WITH THE INDIRECT NOREPINEPHRINE-RELEASING ACTIONS OF METARAMINOL & MAY LIMIT ITS EFFICACY. /BITARTRATE/

CARDIAC OUTPUT INCREASES STRIKINGLY WHEN SLOWING OF THE HEART IS PREVENTED BY ATROPINE.

化学と産業

薬理情報

ATC Code · 2 件

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingApproximately 45%
Pharmacodynamics · 1 件

Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol acts on both α1-adrenergic receptors but appears to have no effect on β-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels.

Mechanism of Action · 4 件

Metaraminol acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic & diastolic). Its effect is thought to be associated with the inhibition of adenyl cyclase which leads to an inhibition of the production of cAMP. Another effect of Metaraminol is that it releases norepinephrine from its storage sites indirectly.

BY DIRECT ACTION ON ALPHA ADRENERGIC RECEPTORS & INDIRECT ACTION THROUGH THE RELEASE OF NOREPINEPHRINE FROM STORAGE SITES...PRODUCES VASOCONSTRICTION, INCREASED PERIPHERAL VASCULAR RESISTANCE, & A RESULTANT INCREASED BLOOD PRESSURE. REFLEX BRADYCARDIA USUALLY OCCURS &...RENAL & CEREBRAL BLOOD FLOW DECREASES. /BITARTRATE/

CARDIAC INOTROPY INCREASES, BUT LESS SO THAN WITH NOREPINEPHRINE & CARDIAC OUTPUT REMAINS UNCHANGED OR MAY SLIGHLY DECREASE IF BRADYCARDIA OCCURS. SOME BETA ADRENERGIC MEDIATED VASODILATION OCCURS WITH METARAMINOL, BUT ALPHA EFFECTS PREDOMINATE. /BITARTRATE/

FOLLOWING IV ADMIN OF 1.5 MG/KG TO RABBITS, THERE WAS A POSITIVE CORRELATION BETWEEN PLASMA DRUG LEVEL & ITS VASOPRESSOR EFFECT. DRUG IS APPARENTLY DIRECT-ACTING SYMPATHOMIMETIC AMINE & ITS ACTION IS PROBABLY TERMINATED BY ITS DILUTION IN BODY FLUIDS & TISSUE UPTAKE.

Metabolism/Metabolites · 2 件

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
54-49-9
PubChem CID
5906
DTXSID
DTXSID8023268
ChEMBL
CHEMBL1201319
ChEBI
CHEBI:6794
UNII
818U2PZ2EH
Nikkaji
J4.155F

WHITE CRYSTALLINE POWDER /BITARTRATE/

物理化学的性質

融点
107.5 °C · 107.5°C
沸点
295.79 °C · 295.79°C (rough estimate)
比重(密度)
1.1222 · 1.1222 (rough estimate)
屈折率
1.476 · 1.4760 (estimate)
酸解離定数(Pka)
8.6 · pKa 8.6 (Uncertain)
InChI
InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1
InChIKey
WXFIGDLSSYIKKV-RCOVLWMOSA-N
SMILES
[C@H](C1C=CC=C(C=1)O)(O)[C@@H](N)C

化学的性質

化学的特性Colourless solid

THE ANTIBACTERIAL ACTION OF FURAZOLIDONE IS ACCOMPANIED BY PROGRESSIVE & GENERALIZED INHIBITION OF MONOAMINE OXIDASE & THE CONCURRENT OR SUBSEQUENT ADMIN OF /METARAMINOL/...COULD RESULT IN A HYPERTENSIVE CRISIS. /BITARTRATE/

For more Interactions (Complete) data for METARAMINOL (20 total), please visit the HSDB record page.

Human Toxicity Excerpts · 4 件

OVERDOSES...CAN CAUSE HYPERTENSIVE CRISES & CARDIAC TACHYARRHYTHMIAS. EVEN IN ABSENCE OF A HYPERTENSIVE EFFECT, PALLOR, TACHYCARDIA, PALPITATION, PRECORDIAL PAIN, WEAKNESS, DIZZINESS, TREMOR, RESPIRATORY DISTRESS, & ANXIETY CAN OCCUR. /BITARTRATE/

TACHYPHYLAXIS MAY DEVELOP AFTER PROLONGED ADMIN, PRESUMABLY SECONDARY TO NOREPHINEPHRINE DEPLETION FROM STORAGE SITES. A DECREASE IN PLASMA VOLUME MAY ALSO OCCUR AS POST-CAPILLARY VASOCONSTRICTION PRODUCES TRANSUDATION OF FLUID INTO EXTRACELLULAR SPACE. /BITARTRATE/

...SUBCUTANEOUS TISSUE NECROSIS OCCURS ONLY RARELY, BUT THE LONGER DURATION OF ACTION MAY BE HAZARDOUS IF OVERDOSAGE & UNINTENTIONAL HYPERTENSION OCCURS. FURTHERMORE, HYPOTENSION MAY RECUR AFTER PROLONGED USE, POSSIBLY SECONDARY TO NOREPINEPHRINE DEPLETION. /BITARTRATE/

Overdosage may result in severe hypertension, cerebral hemorrhage, convulsions, acute pulmonary edema, cardiac arrest, and/or arrhythmias. Headache may be a symptom of hypertension.

Non-Human Toxicity Excerpts · 4 件

/IN A STUDY USING/ ... THE EMBRYONATED CHICKEN EGG ... METARAMINOL ... AFFECTED TERATOGENIC CHANGES THAT CONSISTED OF CEPHALIC HEMATOMA & SKIN & EXTREMITY HEMORRHAGES.

WHEN METARAMINOL WAS ADMIN TO PREGNANT EWES NEAR TERM, UTERINE BLOOD FLOW DECREASED 45%. METARAMINOL CONSISTENTLY DECREASED UTERINE BLOOD FLOW AT ALL LEVELS OF MATERNAL BLOOD PRESSURE ELEVATION.

1 UG/100 G IV DOSES, PRODUCED HYPERTENSIVE EFFECT IN RATS BY STIMULATION OF VASCULAR RECEPTORS, LIBERATION OF ENDOGENOUS ADRENERGIC CATECHOL AMINES, DEPLETION OF HEART CATECHOL AMINES, & LOWER ADRENAL NORADRENALINE STORES. REPEATED ADMIN PRODUCED TACHYPHYLAXIS.

INTRACEREBRAL ADMIN OF METARAMINOL IN MICE & CATS DEPRESSED SPONTANEOUS MOTOR ACTIVITY & INDUCED MODERATE CATALEPSY, PTOSIS, & HIBERNATION. EEG PATTERNS OF CAT SENSORY CORTEX SHOWED MODERATE INITIAL AROUSAL PATTERN FOR 30 MIN AFTER A MARKED SLEEP PATTERN.

Non-Human Toxicity Values · 5 件

LD50 Rat oral 240 mg/kg

LD50 Rat ip 41 mg/kg

LD50 Rat sc 117 mg/kg

LD50 Mouse oral 99 mg/kg

For more Non-Human Toxicity Values (Complete) data for METARAMINOL (6 total), please visit the HSDB record page.

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

有毒物質データの
54-49-9(Hazardous Substances Data)

Hepatic

THE FACT THAT METARAMINOL, 1-(M-HYDROXYNOREPHEDRINE), REMAINED UNCHANGED & BOUND TO TISSUES FOR 1-2 WK AFTER INGESTION PROMPTED IN VITRO STUDIES, WHICH SHOWED THAT THE DRUG RESISTS BIOTRANSFORMATION BY LIVER ENZYMES WHICH METABOLIZE STRUCTURALLY RELATED COMPOUNDS. /MAMMAL SPECIES NOT LISTED IN SOURCE/

MeSH Pharmacological Classification · 3 件

Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.

Drugs used to cause constriction of the blood vessels.

Compounds that bind to and activate ADRENERGIC ALPHA-1 RECEPTORS.

Absorption, Distribution and Excretion · 5 件

The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection.

METARAMINOL IS ABSORBED AFTER ORAL ADMINISTRATION.

METARAMINOL WAS TAKEN UP BY THE RABBIT HEART IN MEASURABLE QUANTITIES FOR AT LEAST 8 DAYS FOLLOWING A SINGLE IV INJECTION. IT WAS EXTENSIVELY DISTRIBUTED IN HEART, LUNGS, LIVER, KIDNEYS, & SKELETAL MUSCLE & POORLY IN THE SPLEEN, BRAIN, FAT, & STOMACH.

EXCEPT FOR THE BRAIN, PERIPHERALLY ADMIN METARAMINOL WAS WELL DISTRIBUTED IN RATS. ORGANS WITH A LARGE POPULATION OF NOREPINEPHIRINE (NE) STORAGE VESICLES SUCH AS THE HEART, SPLEEN, & ADRENAL, TOOK UP RELATIVELY LARGE AMT & RETAINED IT LONGER THAN LIVER, LUNG & KIDNEY.

METARAMINOL IS ABSORBED AFTER ORAL ADMIN; HOWEVER, FOR EQUAL EFFECTS, ORAL DOSES MUST BE 5 OR 6 TIMES GREATER THAN DOSES GIVEN IM OR IV. THE PRESSOR EFFECT OF AN IM DOSE OF 5 MG LASTS FOR ABOUT 1.5 HOURS.

Cellular LocationsMembrane

用途と製造

Uses · 4 件

Therap cat: Adrenergic

MEDICATION (VET)

...for prevention and treatment of the acute hypertensive state occurring with spinal anesthesia. /Bitartrate/

A sympathomimetic drug with prominent direct effects on vascular alpha-adrenergic receptors. Metaraminol is also an indirectly acting agent that stimulates the release of norepinephrine. ...had been used in the treatment of hypotensive states or to relieve attacks of paroxysmal atrial tachycardia, particularly those associated with hypotension.

Methods of Manufacturing · 3 件

Prepn: from m-hydroxyisonitrosopropiophenone.

...from l-m-hydroxyphenylacetylcarbinol.

M-HYDROXYBENZALDEHYDE IS FERMENTED WITH YEAST...TO YIELD M-(HYDROXYPHENYL) ACETYLCARBINOL.../&/ CONDENSATION.../WITH BENZYLAMINE IS/ FOLLOWED BY HYDROGENATION OF C=N LINKAGE & REDUCTIVE CLEAVAGE... METARAMINOL... IS PURIFIED &...CONVERTED TO BITARTRATE BY DISSOLVING IN ETHANOL & REACTING...WITH...TARTARIC ACID.

Formulations/Preparations · 1 件

METARAMINOL BITARTRATE USP (ARAMINE), IS AVAILABLE IN 1-ML AMPULS & 10-ML VIALS AS A STERILE SOLN (10 MG/ML) FOR INTRAMUSCULAR INJECTION, USUALLY IN DOSE OF 5-10 MG, OR, AFTER SUITABLE DILUTION, FOR IV INFUSION. RATE OF ADMIN IS REGULATED ACCORDING TO THE INDIVIDUAL'S RESPONSE TO THE DRUG. /BITARTRATE/

Use ClassificationPharmaceuticals
General Manufacturing InformationVET: MAY DISCOLOR POLYETHYLENE TUBING OR DEVICES.
応用分野 · 2 件

使用Metaraminol is a sympathomimetic amine of both direct and indirect action that has hemodynamic characteristics similar to norepinephrine. It has the ability to elevate both systolic and diastolic blood pressure. It is used in hypotensive shock for the purpose of elevating blood pressure, which can result from spinal anesthesia, surgical complications, and head trauma.

一般的な説明Metaraminol is the N-desmethyl- -methylanalog of phenylephrine. It possesses a mixed mechanismof action, with its direct-acting effects mainly on 1-receptors. It is used parenterally as a vasopressor in thetreatment and prevention of the acute hypotensive stateoccurring with spinal anesthesia. It also has been used totreat severe hypotension brought on by other traumas thatinduce shock.

上流・下流製品情報

上流原料

3-ヒドロキシベンズアルデヒド2,3-ジヒドロキシブタン二酸Ethanol solutionL-(+)-酒石酸1-アミノエタノール水素亜硝酸ブチル
補足説明 · 1 件

定義ChEBI: A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.